107 related articles for article (PubMed ID: 26264150)
1. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
Novik AV; Protsenko SA; Baldueva IA; Ivantsov AO; Nekhaeva TL; Akhaeva ZY; Yanus GA; Iyevleva AG; Imyanitov EN
Target Oncol; 2016 Apr; 11(2):235-8. PubMed ID: 26264150
[TBL] [Abstract][Full Text] [Related]
2. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.
Schrama D; Groesser L; Ugurel S; Hafner C; Pastrana DV; Buck CB; Cerroni L; Theiler A; Becker JC
JAMA Dermatol; 2014 Nov; 150(11):1180-6. PubMed ID: 24943872
[TBL] [Abstract][Full Text] [Related]
3. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.
Harding JJ; Barker CA; Carvajal RD; Wolchok JD; Chapman PB; Lacouture ME
J Clin Oncol; 2014 May; 32(14):e54-6. PubMed ID: 24470011
[No Abstract] [Full Text] [Related]
4. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
5. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
6. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
Fedorenko IV; Wargo JA; Flaherty KT; Messina JL; Smalley KSM
J Invest Dermatol; 2015 Dec; 135(12):3115-3124. PubMed ID: 26302068
[TBL] [Abstract][Full Text] [Related]
7. Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation.
Kocovski L; Bane A; Tang S; Salama S; Alowami S
Rare Tumors; 2015 May; 7(2):5698. PubMed ID: 26266008
[TBL] [Abstract][Full Text] [Related]
8. Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Alabed YZ; Aghayev A; Sakellis C; Van den Abbeele AD
Clin Nucl Med; 2015 Nov; 40(11):e528-9. PubMed ID: 26284765
[TBL] [Abstract][Full Text] [Related]
9. The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
Woods JA; Ferguson JS; Kalra S; Degabriele A; Gardner J; Logan P; Ferguson J
J Photochem Photobiol B; 2015 Oct; 151():233-8. PubMed ID: 26318280
[TBL] [Abstract][Full Text] [Related]
10. Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report.
Nosaka T; Hiramatsu K; Nemoto T; Saito Y; Ozaki Y; Takahashi K; Naito T; Ofuji K; Matsuda H; Ohtani M; Suto H; Imamura Y; Nakamoto Y
BMC Clin Pathol; 2015; 15():15. PubMed ID: 26346246
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
12. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
[TBL] [Abstract][Full Text] [Related]
13. Trametinib: a MEK inhibitor for management of metastatic melanoma.
Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P
Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206
[TBL] [Abstract][Full Text] [Related]
14. Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.
Latimer NR; Amonkar MM; Stapelkamp C; Sun P
Melanoma Res; 2015 Dec; 25(6):528-36. PubMed ID: 26340744
[TBL] [Abstract][Full Text] [Related]
15. Use of vemurafenib in a patient unable to swallow whole.
Janson B; Whittle J; Witney K; Moodie K; Callahan J; Sandhu S
J Oncol Pharm Pract; 2016 Oct; 22(5):733-7. PubMed ID: 26315107
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients.
Vandersleyen V; Grosber M; Wilgenhof S; De Kock J; Neyns B; Gutermuth J
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1133-5. PubMed ID: 26303964
[TBL] [Abstract][Full Text] [Related]
17. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in the treatment of malignant melanoma: review of the literature.
Mashima E; Inoue A; Sakuragi Y; Yamaguchi T; Sasaki N; Hara Y; Omoto D; Ohmori S; Haruyama S; Sawada Y; Yoshioka M; Nishio D; Nakamura M
Onco Targets Ther; 2015; 8():2045-51. PubMed ID: 26273207
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
[TBL] [Abstract][Full Text] [Related]
20. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development.
Fang L; Lu W; Choi HH; Yeung SC; Tung JY; Hsiao CD; Fuentes-Mattei E; Menter D; Chen C; Wang L; Wang J; Lee MH
Cancer Cell; 2015 Aug; 28(2):183-97. PubMed ID: 26267535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
